Napp Pharmaceuticals Limited
- A10 - Antidiabéticos
- INVOKANA film-coated tablet 100 mg
- INVOKANA film-coated tablet 300 mg
- VOKANAMET film-coated tablet 1 000 mg+50 mg
- VOKANAMET film-coated tablet 850 mg+50 mg
- C08 - Bloqueantes del canal de calcio
- ADIZEM SR prolonged-release capsule, hard 120 mg
- ADIZEM SR prolonged-release capsule, hard 180 mg
- ADIZEM SR prolonged-release capsule, hard 90 mg
- ADIZEM XL prolonged-release capsule, hard 120 mg
- ADIZEM XL prolonged-release capsule, hard 180 mg
- ADIZEM XL prolonged-release capsule, hard 200 mg
- ADIZEM XL prolonged-release capsule, hard 240 mg
- ADIZEM XL prolonged-release capsule, hard 300 mg
- L01 - Antineoplásicos
- HERZUMA powder for solution for infusion 150 mg
- HERZUMA powder for solution for infusion 420 mg
- TRUXIMA concentrate for solution for infusion 100 mg
- TRUXIMA concentrate for solution for infusion 500 mg/50 ml
- L03 - Inmunoestimulantes
- PELMEG PREFILLED SYRINGE solution for injection 6 mg/0.6 ml
- N02 - Analgésicos
- BUTRANS transdermal patch 10 µg/h
- BUTRANS transdermal patch 15 µg/h
- BUTRANS transdermal patch 20 µg/h
- BUTRANS transdermal patch 5 µg/h
- DHC CONTINUS prolonged-release tablet 120 mg
- DHC CONTINUS prolonged-release tablet 60 mg
- DHC CONTINUS prolonged-release tablet 90 mg
- MST CONTINUS prolonged-release granules 100 mg
- MST CONTINUS prolonged-release granules 20 mg
- MST CONTINUS prolonged-release granules 200 mg
- MST CONTINUS prolonged-release granules 30 mg
- MST CONTINUS prolonged-release granules 60 mg
- MST CONTINUS prolonged-release tablet 10 mg
- MST CONTINUS prolonged-release tablet 100 mg
- MST CONTINUS prolonged-release tablet 15 mg
- MST CONTINUS prolonged-release tablet 200 mg
- MST CONTINUS prolonged-release tablet 30 mg
- MST CONTINUS prolonged-release tablet 5 mg
- MST CONTINUS prolonged-release tablet 60 mg
- MXL prolonged-release capsule, hard 120 mg
- MXL prolonged-release capsule, hard 150 mg
- MXL prolonged-release capsule, hard 200 mg
- MXL prolonged-release capsule, hard 30 mg
- MXL prolonged-release capsule, hard 60 mg
- MXL prolonged-release capsule, hard 90 mg
- OXYCONTIN prolonged-release tablet 10 mg
- OXYCONTIN prolonged-release tablet 120 mg
- OXYCONTIN prolonged-release tablet 15 mg
- OXYCONTIN prolonged-release tablet 20 mg
- OXYCONTIN prolonged-release tablet 30 mg
- OXYCONTIN prolonged-release tablet 40 mg
- OXYCONTIN prolonged-release tablet 5 mg
- OXYCONTIN prolonged-release tablet 60 mg
- OXYCONTIN prolonged-release tablet 80 mg
- OXYNORM capsule, hard 10 mg
- OXYNORM capsule, hard 20 mg
- OXYNORM capsule, hard 5 mg
- OXYNORM oral solution 5 mg/5 ml
- OXYNORM oral suspension 10 mg/ml
- OXYNORM solution for injection 10 mg/1 ml
- OXYNORM solution for injection 50 mg/1 ml
- PALLADONE capsule, hard 1.3 mg
- PALLADONE capsule, hard 2.6 mg
- PALLADONE prolonged-release capsule, hard 16 mg
- PALLADONE prolonged-release capsule, hard 2 mg
- PALLADONE prolonged-release capsule, hard 24 mg
- PALLADONE prolonged-release capsule, hard 4 mg
- PALLADONE prolonged-release capsule, hard 8 mg
- PALLADONE solution for injection 10 mg/ml
- PALLADONE solution for injection 2 mg/ml
- SEVREDOL film-coated tablet 10 mg
- SEVREDOL film-coated tablet 20 mg
- SEVREDOL film-coated tablet 50 mg
- TARGINACT prolonged-release tablet 10 mg+5 mg
- TARGINACT prolonged-release tablet 20 mg+10 mg
- TARGINACT prolonged-release tablet 40 mg+20 mg
- TARGINACT prolonged-release tablet 5 mg+2.5 mg
- TRANSTEC transdermal patch 35 µg/h
- TRANSTEC transdermal patch 52.5 µg/h
- TRANSTEC transdermal patch 70 µg/h
- R03 - Agentes contra padecimientos obstructivos de las vías respiratorias
- FLUTIFORM K-HALER pressurised inhalation, suspension 5 µg/dose+125 µg/dose
- FLUTIFORM K-HALER pressurised inhalation, suspension 5 µg/dose+50 µg/dose
- FLUTIFORM pressurised inhalation, suspension 10 µg/dose+250 µg/dose
- FLUTIFORM pressurised inhalation, suspension 5 µg/dose+125 µg/dose
- FLUTIFORM pressurised inhalation, suspension 5 µg/dose+50 µg/dose
- PHYLLOCONTIN CONTINUS prolonged-release tablet 225 mg
- PHYLLOCONTIN CONTINUS prolonged-release tablet 350 mg
- UNIPHYLLIN CONTINUS prolonged-release tablet 200 mg
- UNIPHYLLIN CONTINUS prolonged-release tablet 300 mg
- UNIPHYLLIN CONTINUS prolonged-release tablet 400 mg
- V03 - Todos los demás preparados terapéuticos
- NYXOID SINGLE DOSE nasal spray, solution 1.8 mg